However, since the function of human ZFP106 is not yet clear, it will be important to screen for ZFN106 mutations in early-onset CMT2 cases (42), but also milder forms of CMT, as well as other neurodegenerative disease in which there is degeneration of either motor or sensory neurons, such as ALS and progressive muscular atrophy (PMA). Here, ZNF106 is linked to neurodegenerative disease.